EuroBiotech Report—Roche-Dicerna, GSK in TB, Sanifit data, filgotinib and Novartis

Map of Europe
(Pixabay)

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with Roche, which put up $200 million for the global rights to Dicerna Pharmaceuticals' RNAi treatment for hepatitis B. The deal features $1.5 billion in milestones. Our other four stories are a mixed bag of clinical readouts. GlaxoSmithKline and Sanifit recorded the two successes, posting upbeat phase 2b readouts on a tuberculosis vaccine and renal disease drug, respectively. Galapagos was involved in the two failures. Filgotinib, Galapagos' Gilead Sciences-partnered autoimmune drug, fell short in two indications, and another asset it was working on with MorphoSys and Novartis missed the mark in atopic dermatitis. And more. — Nick Taylor
 
1. Roche pays $200M for rights to Dicerna's hepatitis B RNAi drug

Roche is paying Dicerna Pharmaceuticals $200 million (€179 million) upfront for a global license to phase 1 hepatitis B prospect DCR-HBVS. The deal, which will see Roche and Dicerna collaborate on other hepatitis B virus assets, is worth up to $1.5 billion in milestones.
 
2. GSK tuberculosis vaccine maintains efficacy out to 3 years

GlaxoSmithKline has shared updated data from a phase 2b trial of its tuberculosis vaccine candidate M72/AS01E. Three years after vaccination, protection against active pulmonary tuberculosis disease remained up around 50%, suggesting the candidate provides lasting immunity against the bacterium.
 
3. Sanifit's calcification drug hits goal in renal disease phase 2b

Sponsored by BHE

[Webinar] State of Data Analytics and Machine Learning in the Life Sciences Industry: 2020 Benchmarking Survey

Thursday, June 25, 2020 | 2:00pm ET | 11:00am PT

Join us Thursday, June 25th for a look at the current state of analytics in the life sciences industry. We will present the results from our industry survey with FiercePharma on how 100 of your peers are leveraging data analytics to respond to today’s challenges and generate timely, high value insights.

A phase 2b trial of Sanifit’s SNF472 in hemodialysis patients has hit its primary endpoint, teeing the Spanish biotech up to take the calcification inhibitor forward.
 
4. Gilead's filgotinib fails midphase tests in lupus, Sjogren's

A clutch of Gilead Sciences drugs including filgotinib have failed to move the needle in mid-phase clinical trials of cutaneous lupus and Sjogren's syndrome patients. Neither trial hit the primary endpoint, although Gilead did see “evidence of activity” in patients taking filgotinib.

5. Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos

MorphoSys and Galapagos are cutting off development of their Novartis-backed drug MOR106 in atopic dermatitis.
 
And more articles of note>>

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.